Fortified antibiotic agents are needed for the management of keratitis

Article

An investigation in the Journal of Cataract and Refractive Surgery strongly suggests the use of fortified antibiotic agents for prevention of vision loss in infectious keratitis patients.

An investigation in the Journal of Cataract and Refractive Surgery strongly suggests the use of fortified antibiotic agents for prevention of vision loss in infectious keratitis patients.

Dr Vitoria de Rojas et al., Instituto Oftalmológico Europeo, Coruña, Spain, conducted a multicentred case series study on 9794 patients with infectious keratitis who underwent surface ablation between January 2003 and December 2009. The main outcome measures included incidence of infectious keratitis after surface ablation, ulture results, response to treatment, and visual outcomes. The team recorded incidence, risk factors, clinical course, days to diagnosis, medical and surgical treatment, and visual outcome.

Infectious keratitis after surface ablation was found in 39 eyes of 38 patients and the onset of infection occurred within 7 days of surgery in 28 cases. From the samples taken it was found that 13 of 27 cases had positive cultures- with the most frequent microorganism being the Staphylococcus species in 9 patients.

In 23 patients the final corrected distance visual acuity (CDVA) was 20/20 or better, 20/40 or better in 36 patients and worse then 20/40 in 3 patients. The occurrence of infectious keratitis after surface ablation was 0.20% and was considered potentially sight threatening.

The study suggested the immediate use of fortified antibiotic agents for the management of infectious keratitis- meaning vision is more likely to be preserved in most incidences.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.